Vis enkel innførsel

dc.contributor.authorAlopaeus, Julia Fredrika
dc.contributor.authorHagesæther, Ellen
dc.contributor.authorTho, Ingunn
dc.date.accessioned2019-01-26T14:50:51Z
dc.date.accessioned2019-01-28T13:56:06Z
dc.date.available2019-01-26T14:50:51Z
dc.date.available2019-01-28T13:56:06Z
dc.date.issued2019
dc.identifier.citationAlopaeus, J.F, Hagesæther, E. & Tho, I.T. (2019). Micellisation mechanism and behaviour of Soluplus®–furosemide micelles: Preformulation studies of an oral nanocarrier-based system. Pharmaceuticals, 12(1)en
dc.identifier.issn1424-8247
dc.identifier.issn1424-8247
dc.identifier.urihttps://hdl.handle.net/10642/6560
dc.description.abstractIn this study, self-assembling Soluplus® micelles were examined for inherent properties. Through calorimetric analysis, the critical micelle concentration (CMC) could be determined at 25 and 37 °C, and the influence of three media (Milli-Q water, phosphate-buffered saline (PBS) with a pH of 7.4 and 0.1 M HCl) on the lower critical solution temperature (LCST) was detected. Furthermore, the solubilisation of a poorly soluble drug, furosemide, into the Soluplus® micelles was studied. The concentration-dependent properties of the micellar system were assessed through an examination of the micellar size, polydispersity, morphology, viscosity and solubilising properties, which were all found to be affected by the concentration, but temperature, pH and the composition of the test medium were also found to have an effect. Homogeneity in the estimated micellar size and morphology was shown for monophasic micelle dispersions in lower concentrations and with a shift towards more complex structures or aggregates in higher concentrations. The micelles were further investigated in terms of drug release and biocompatibility with mucus-producing HT29-MTX cells, where no biocompatibility issues were found. In this research, the implications for oral drug delivery are discussed and valuable preformulation information is provided on the micellar properties of a Soluplus® drug system in a liquid or semi-solid form.en
dc.language.isoenen
dc.publisherMDPIen
dc.relation.ispartofseriesPharmaceuticals;12(1)
dc.rights© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).en
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectFurosemidesen
dc.subjectGraft copolymersen
dc.subjectNano drug carriersen
dc.subjectOral administrationsen
dc.subjectSelf-assemblingsen
dc.subjectSolubilisationen
dc.titleMicellisation mechanism and behaviour of Soluplus®–furosemide micelles: Preformulation studies of an oral nanocarrier-based systemen
dc.typeJournal articleen
dc.typePeer revieweden
dc.date.updated2019-01-26T14:50:51Z
dc.description.versionpublishedVersionen
dc.identifier.doihttps://dx.doi.org/10.3390/ph12010015
dc.identifier.cristin1663218
dc.source.journalPharmaceuticals


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Med mindre annet er angitt, så er denne innførselen lisensiert som © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).